TEST:

pstateDx™ test

The pstateDx™ test promises demonstrated clinical utility in stratification of Benign Prostate Cancer Hyperplasia (BPH) from Prostate Cancer; thus, leading to the reduction of false positives and, as a result, less need for prostate biopsies. The pstateDx™ test addresses this unmet need with exceptionally competitive demonstrated accuracy using serum-based testing (non-PSA based test). Using BPGbio’s AI-powered Interrogative Biology® platform, BPGbio identified, developed and validated a biomarker diagnostic that demonstrated promising clinical utility in stratifying BPH from prostate cancer.